Assessing adrenal function in children with leukemia after glucocorticoid treatment
Official title: A Swiss Prospective Multicenter Longitudinal Assessment of Hypothalamic-pituitary-adrenal Axis Suppression After Glucocorticoid Therapy for Leukemia and Lymphoblastic Lymphoma in Children: An Explorative Study
Run by University Children's Hospital Basel · NCT06861530 · Data updated 2026-11-12
This study is trying to see how glucocorticoid treatment affects the adrenal function in children with leukemia to better understand and manage any potential hormone problems they might have after treatment.
Quick facts
| Study type | Observational |
|---|---|
| Ages | Any age to 18 Years |
| Sex | All |
| Enrollment | 40 (estimated) |
| Sponsor | University Children's Hospital Basel Academic / other |
| Drugs / interventions | chemotherapy |
| Locations | 2 sites (Aarau and 1 other locations) |
| Status | Recruiting |
| Started | August 13, 2024 |
| Main results expected | December 31, 2026 |
| Study ends | December 31, 2026 |
| Registry record updated | May 8, 2026 |
| Trial ID | NCT06861530 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are children diagnosed with acute lymphoblastic leukemia or lymphoblastic lymphoma who are receiving glucocorticoid therapy.
✕Probably not a fit
Patients who do not have a diagnosis of ALL or LBL or those who have contraindications to intravenous synthetic ACTH will not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational study aims to evaluate the suppression of the hypothalamic-pituitary-adrenal (HPA) axis in children diagnosed with acute lymphoblastic leukemia (ALL) or lymphoblastic lymphoma (LBL) who have received glucocorticoid therapy. The study will monitor the natural production of glucocorticoids in these patients after treatment, as glucocorticoids can lead to adrenal insufficiency, which poses additional health risks. The research will take place at the University Children's Hospital Basel and the Children's Hospital of Aarau, focusing on children treated with glucocorticoids for at least 21 days. The findings may help identify and manage adrenal insufficiency in this vulnerable population.
Why it matters
Potential benefit: If successful, this study could improve the detection and management of adrenal insufficiency in children undergoing treatment for leukemia.
How similar studies have gone: While there is existing literature on glucocorticoid effects, this specific assessment of HPA axis suppression in pediatric leukemia patients is relatively novel.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * diagnosed with ALL or LBL * treated for at least 21 sequential days with glucocorticoids between the 01.07.2024 and the 30.06.2027 at the Childrens University Hospital of Basel or at the Childrens Hospital of Aarau * lnformed consent can be obtained from the patient\'s legal representatives (and the patient if at least 14 years of age) within week 2 of treatment with glucocorticoids Exclusion Criteria: \- Contraindication to the administration of intravenous synthetical ACTH (Synacthen®): extremely rare cases of known or suspected hypersensitivity to Synacthen®.
Where it's running
-
Ksa
Aarau, Switzerland Recruiting -
Ukbb
Basel, Switzerland Recruiting
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Adrenal Function in RA Patients on Low-Dose Corticosteroids
This study tests how common adrenal insufficiency is among rheumatoid arthritis patients who are taking low-dose corticosteroids.
-
Normal ranges and diagnostic cut-offs for salivary cortisol
This project will test two saliva cortisol methods — a lab LC‑MS assay and a rapid fluorescence immunoassay — to find normal ranges and the best diagnostic cut-offs for adults with suspected Cushing syndrome or adrenal insufficiency.
-
CTD402 for relapsed or refractory T-ALL and T-LBL
This trial will test whether a single infusion of CTD402 UCART can be safe and shrink cancer in people age 12 and older with relapsed or refractory T‑cell acute lymphoblastic leukemia or lymphoblastic lymphoma.
-
Evaluating adrenal insufficiency after surgery in patients with primary aldosteronism
This study is testing how often people with primary aldosteronism develop adrenal insufficiency after having surgery to remove their adrenal glands.
-
Investigating the role of CD9 gene regulation in childhood leukemia relapses
This study looks at how the CD9 gene might affect relapses in children with B-acute lymphoblastic leukemia to help find better ways to diagnose and treat the disease.
-
Treatment for adrenal insufficiency in patients with Cushing syndrome using osilodrostat
This study is testing if the medication osilodrostat, combined with a specific dose of another steroid, can help people with Cushing syndrome avoid adrenal insufficiency while keeping their hormone levels balanced.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.